Clinical Trials Using Niraparib Tosylate Monohydrate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Niraparib Tosylate Monohydrate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

    This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.
    Location: 14 locations

  • Niraparib and Tumor-Treating Fields for the Treatment of Recurrent Glioblastoma

    This phase II trial evaluates the safety and effectiveness of an investigational drug called niraparib in combination with tumor-treating fields for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrence). Niraparib makes it harder for tumor cells to repair their DNA (the instructions inside the tumor cell that make it grow), which can lead to the death of tumor cells. Electric forces called tumor-treating fields may disrupt the growth of tumor cells. These tumor-treating fields are given to patients using a device called Optune. Giving niraparib and tumor-treating fields together may work better than the individual use of each intervention for the treatment of patients with recurrent glioblastoma.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Niraparib before Surgery in Treating Patients with High Risk Localized Prostate Cancer and DNA Damage Response Defects

    This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Abiraterone Acetate, Prednisone, Leuprolide, Niraparib, and Stereotactic Body Radiotherapy for the Treatment of High Risk or Node Positive Prostate Cancer, The ASCLEPIuS Trial

    This phase I / II trial investigates the best dose of niraparib and how well it works when given together with abiraterone acetate, prednisone, leuprolide, and stereotactic body radiotherapy in treating patients with high risk or node positive prostate cancer. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Abiraterone acetate and leuprolide may fight prostate cancer by lowering the amount of testosterone made by the body. Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Stereotactic body radiotherapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving niraparib together with abiraterone acetate, prednisone, leuprolide and stereotactic body radiotherapy may kill more tumor cells.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan